NCT02139410

IGF-1, Sarcopenia and Mortality: a Cohort Study in Patient With Cognitive Impairment

Insulin Like Growth Factor 1 and Risks of Sarcopenia and Mortality in Patients With Cognitive Impairment

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 589 (actual)
• Sponsor: University of Roma La Sapienza · Academic / Other
• Sex: All
• Age: 65 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Insulin-like growth factor 1 (IGF)-1 is an important neuromyotrophic hormone. Disregulation of this hormone has been reported to influence the genesis of cognitive impairment and dementia in the elderly patients. We analyzed the possible link between IGF-1 and risk of Sarcopenia and Mortality in a cohort of elder patients with cognitive impairment.

Conditions

• Cognitive Impairment
• Insulin-like Growth Factor 1

Interventions

Type	Name	Description
PROCEDURE	IGF-1 serum value	Evaluation of IGF-1 serum value at baseline, 24 and 48 months

Timeline

• Start date: 2008-06-01
• Primary completion: 2013-09-01
• Completion: 2013-11-01
• First posted: 2014-05-15
• Last updated: 2014-05-15

Locations

2 sites across 1 country: Italy